Demographics and clinical features of ATLL patients
| Category . | Acute (n = 80) . | Lymphomatous (n = 96) . | Unfavorable chronic (n = 7) . | Chronic (n = 5) . | Smoldering (n = 3) . | Unclassified (n = 4) . | All groups (N = 195) . |
|---|---|---|---|---|---|---|---|
| Age, median, y | 54 | 50 | 53 | 69 | 40 | 50 | 52 |
| Sex, n (%) | |||||||
| Female | 49 (61) | 53 (55) | 4 (57) | 4 (80) | 0 | 2 (50) | 112 (54) |
| Male | 30 (38) | 42 (44) | 3 (43) | 1 (20) | 3 (100) | 2 (50) | 81 (42) |
| Unknown | 1 (1) | 1 (1) | — | — | — | — | 2 (4) |
| Ethnicity, n (%) | |||||||
| Hispanic | 6 (8) | 13 (12.5) | 1 (14) | 1 (20) | 1 (33) | 1 (25) | 21 (11) |
| African American | 9 (11) | 13 (14) | 0 | 0 | 0 | 2 (50) | 24 (12) |
| Afro-Caribbean | 65 (81) | 69 (75) | 6 (86) | 4 (80) | 2 (67) | 1 (25) | 150 (77) |
| Unknown | — | 1 (0.5) | — | — | — | — | 1 (0.5) |
| Stage, n (%) | |||||||
| I-II | — | 13 (14) | — | — | — | — | 13 (6) |
| III-IV | 80 (100) | 70 (74) | 7 (100) | 5 (100) | 3 (100) | 1 (33) | 166 (85) |
| Undetermined | — | 13 (13) | — | — | — | 3 (67) | 16 (9) |
| Hypercalcemia, n (%) | 52 (65) | 22 (23) | 0 | 0 | 0 | — | — |
| LDH, n (%) | |||||||
| Normal | 8 (10) | 16 (17) | — | 3 (60) | 1 (33) | — | 28 (15) |
| <2× normal | 6 (8) | 16 (17) | 6 (86) | 2 (40) | 2 (67) | — | 32 (17) |
| ≥2× normal | 59 (73) | 34 (35) | — | 0 | 0 | — | 93 (49) |
| Undetermined | 7 (9) | 30 (31) | 1 (14) | 0 | 0 | — | 38 (19) |
| Comorbidities, n (%) | |||||||
| HIV | 4 (5) | 12 (12) | — | — | — | 1 (25) | 17 (9) |
| HAM/TSP | 2 (2.6) | 2 (2) | 1 (14) | 1 (33) | 1 (25) | — | 6 (3) |
| Strongyloidiasis | 1 (1.3) | 1 (1) | 1 (14) | — | 2 (75) | — | 5 (2.6) |
| Hepatitis B | — | 2 (2) | — | — | — | 1 (25) | 3 (1.6) |
| Pneumocystis | 2 (2.6) | 1 (1) | — | — | — | — | 3 (1.6) |
| Neurocysticercosis | 1 (1.3) | 1 (1) | — | — | — | — | 2 (1) |
| Hepatitis C | — | 1 (1) | — | — | — | 1 (25) | 2 (1) |
| Scabies | 1 (1.3) | — | — | — | — | — | 1 (0.5) |
| Cryptococcus | 1 (1.3) | — | — | — | — | — | 1 (0.5) |
| Tuberculosis (lung) | — | — | — | — | 1 (25) | — | 1 (0.5) |
| Toxoplasmosis | 1 (1.3) | — | — | — | — | — | 1 (0.5) |
| Extranodal Involvement, n (%) | 80 (100) | 79 (79) | 7 (100) | 3 (100) | 4 (100) | 4 (100) | 173 (89) |
| Marrow* | 47 (62) | 12 (12) | 4 (57) | 2 (67) | 3 (75) | 2 (50) | 70 (36) |
| Skin | 24 (32) | 22 (22) | 3 (43) | 2 (67) | 2 (50) | 2 (50) | 55 (28) |
| Bone | 6 (8) | 21 (21) | — | — | — | — | 27 (14) |
| Lung | 12 (16) | 12 (12) | 1 (14) | — | 1 (25) | — | 26 (13) |
| Hepatic | 15 (20) | 8 (8) | — | — | — | — | 23 (12) |
| CNS | 7 (9) | 5 (5) | — | — | — | — | 12 (7) |
| Category . | Acute (n = 80) . | Lymphomatous (n = 96) . | Unfavorable chronic (n = 7) . | Chronic (n = 5) . | Smoldering (n = 3) . | Unclassified (n = 4) . | All groups (N = 195) . |
|---|---|---|---|---|---|---|---|
| Age, median, y | 54 | 50 | 53 | 69 | 40 | 50 | 52 |
| Sex, n (%) | |||||||
| Female | 49 (61) | 53 (55) | 4 (57) | 4 (80) | 0 | 2 (50) | 112 (54) |
| Male | 30 (38) | 42 (44) | 3 (43) | 1 (20) | 3 (100) | 2 (50) | 81 (42) |
| Unknown | 1 (1) | 1 (1) | — | — | — | — | 2 (4) |
| Ethnicity, n (%) | |||||||
| Hispanic | 6 (8) | 13 (12.5) | 1 (14) | 1 (20) | 1 (33) | 1 (25) | 21 (11) |
| African American | 9 (11) | 13 (14) | 0 | 0 | 0 | 2 (50) | 24 (12) |
| Afro-Caribbean | 65 (81) | 69 (75) | 6 (86) | 4 (80) | 2 (67) | 1 (25) | 150 (77) |
| Unknown | — | 1 (0.5) | — | — | — | — | 1 (0.5) |
| Stage, n (%) | |||||||
| I-II | — | 13 (14) | — | — | — | — | 13 (6) |
| III-IV | 80 (100) | 70 (74) | 7 (100) | 5 (100) | 3 (100) | 1 (33) | 166 (85) |
| Undetermined | — | 13 (13) | — | — | — | 3 (67) | 16 (9) |
| Hypercalcemia, n (%) | 52 (65) | 22 (23) | 0 | 0 | 0 | — | — |
| LDH, n (%) | |||||||
| Normal | 8 (10) | 16 (17) | — | 3 (60) | 1 (33) | — | 28 (15) |
| <2× normal | 6 (8) | 16 (17) | 6 (86) | 2 (40) | 2 (67) | — | 32 (17) |
| ≥2× normal | 59 (73) | 34 (35) | — | 0 | 0 | — | 93 (49) |
| Undetermined | 7 (9) | 30 (31) | 1 (14) | 0 | 0 | — | 38 (19) |
| Comorbidities, n (%) | |||||||
| HIV | 4 (5) | 12 (12) | — | — | — | 1 (25) | 17 (9) |
| HAM/TSP | 2 (2.6) | 2 (2) | 1 (14) | 1 (33) | 1 (25) | — | 6 (3) |
| Strongyloidiasis | 1 (1.3) | 1 (1) | 1 (14) | — | 2 (75) | — | 5 (2.6) |
| Hepatitis B | — | 2 (2) | — | — | — | 1 (25) | 3 (1.6) |
| Pneumocystis | 2 (2.6) | 1 (1) | — | — | — | — | 3 (1.6) |
| Neurocysticercosis | 1 (1.3) | 1 (1) | — | — | — | — | 2 (1) |
| Hepatitis C | — | 1 (1) | — | — | — | 1 (25) | 2 (1) |
| Scabies | 1 (1.3) | — | — | — | — | — | 1 (0.5) |
| Cryptococcus | 1 (1.3) | — | — | — | — | — | 1 (0.5) |
| Tuberculosis (lung) | — | — | — | — | 1 (25) | — | 1 (0.5) |
| Toxoplasmosis | 1 (1.3) | — | — | — | — | — | 1 (0.5) |
| Extranodal Involvement, n (%) | 80 (100) | 79 (79) | 7 (100) | 3 (100) | 4 (100) | 4 (100) | 173 (89) |
| Marrow* | 47 (62) | 12 (12) | 4 (57) | 2 (67) | 3 (75) | 2 (50) | 70 (36) |
| Skin | 24 (32) | 22 (22) | 3 (43) | 2 (67) | 2 (50) | 2 (50) | 55 (28) |
| Bone | 6 (8) | 21 (21) | — | — | — | — | 27 (14) |
| Lung | 12 (16) | 12 (12) | 1 (14) | — | 1 (25) | — | 26 (13) |
| Hepatic | 15 (20) | 8 (8) | — | — | — | — | 23 (12) |
| CNS | 7 (9) | 5 (5) | — | — | — | — | 12 (7) |
Patients with acute and chronic ATLL usually have bone marrow involvement. The above percentage represents patients tested only.